Street Calls of the Week
Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector Plasmid DNA technology.
The partnership expands on an existing relationship between the two companies, which previously centered on Plasmid DNA production. Under the new agreement, Genenta will make its clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients.
"Our expanded collaboration with ANEMOCYTE represents a natural progression of a successful partnership in plasmid DNA manufacturing," said Pierluigi Paracchi, CEO at Genenta Science. "By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry."
The technology platform was developed from foundational research by Professor Luigi Naldini, co-founder of Genenta. ANEMOCYTE will use the platform to enhance its offerings, providing clients with high-quality materials from R&D to GMP grade, spanning preclinical to commercial stages.
ANEMOCYTE, a provider of advanced therapy and nucleic acids solutions, views the formalized partnership as a way to ensure clients have access to a robust platform for their advanced therapy programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.